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Acute generalized exanthematous pustulosis (AGEP) is 
manifested by rapid development of many sterile, non- 
follicular pustules on a background of edematous erythema. 
More than 90 percent of AGEP are induced by medication, 
mostly antibiotics. Drug patch test can be helpful in the 
diagnosis of AGEP. This paper reports the first case of 
celecoxib-induced AGEP confirmed by patch test in Korean 
literature. (Ann Dermatol 23(S3) S380∼S382, 2011)
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INTRODUCTION
Acute generalized exanthematous pustulosis (AGEP) is an 
uncommon eruption characterized by acute occurrence of 
many non-follicular sterile pustules on edematous ery-
thema. More than 90 percent of AGEP are induced by 
medication and most of them are antibiotics
1. Other eti-
ologic agents include viral infection, mercury and lac-
quer
2,3. Celecoxib is a non-steroidal anti-inflammatory 
drug which inhibits cyclooxygenase-2 (COX-2) and pres-
cribed for control of pain. In English literature, three cases 
of celecoxib induced AGEP had been reported
4-6. We 
report a first case of AGEP induced by celecoxib con-
firmed by patch test in Korean literature.
CASE REPORT
A 53-year-old Korean woman without any history of 
allergy and psoriasis presented with disseminated pustules 
on the face and trunk. The patient had fever and itching. 
From two weeks before visiting our hospital, she started to 
take celecoxib for her shoulder pain. Ten days after taking 
medication, erythematous skin eruption with high fever 
had developed, and she stopped taking celecoxib. After 
two days, numerous small pustules developed in these 
erythematous lesions. Physical examination revealed 
many tiny non-follicular pustules on the face (Fig. 1A) and 
trunk (Fig. 1B). The skin lesion was accompanied by 
leukocytosis (10.17×10
3/μl) with elevated neutrophil 
counts (8.39×10
3/Ml) and C-reactive protein levels (7.32 
mg/dl). No microrganism was identified in blood cultures 
and pustule cultures. Skin biopsy perfomed on the pa-
tient's back revealed subconeal pustules, spongiosis in the 
epidermis, papillary dermal edema and perivascular infil-
tration of lymphocytes, neutrophils and some eosinophils 
on papillary dermis (Fig. 2). On admission, the patient was 
treated with methylprednisolone 40 mg twice a day and 
improved within seven days. AGEP induced by celecoxib 
was the most likely suspect. After three months, a drug 
patch test was performed with celecoxib diluted at 5 
percent in normal saline and in petrolatum. To determine 
whether the constituents of the capsule caused AGEP, 
constituents of the capsule were diluted at 5 percent in 
normal saline and in petrolatum; these were also included A Case of Celecoxib Induced Acute Generalized Exanthematous Pustulosis
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Fig. 1. (A) Numerous tiny non- 
follicular pustules on the face. (B) 
A hundred of non-follicular pustules
on the back.
Fig. 2. (A) Subconeal pustules in the
epidermis (H&E, ×200). (B) Peri-
vascular infiltration of lymphocytes 
and eosinophils in the upper dermis
(H&E, ×400).
in patch test. At the same time, several other antibiotics 
and non-steroidal anti-inflammatory drugs were tested, but 
sulfonamide drugs were not included. To rule out false- 
positive reactions, two healthy persons were also tested. 
The patient showed strong vesicular reaction to celecoxib 
diluted at 5 percent in normal saline (Fig. 3) and ery-
thematous reaction to celecoxib diluted at 5 percent in 
petrolatum. The result for other drugs was negative. It was 
concluded that celecoxib was the cause of AGEP.
DISCUSSION
When Baker and Ryan
7 reported 104 cases of pustular 
psoriasis in 1968, they found five patients who had no 
history of psoriasis, rapidly progressing and with quick 
improvement. In 1980 Beylot et al.
8 introduced the term 
AGEF.
AGEP is a rare and severe pustular reaction of drug 
eruption characterized by acute, extensive, non-follicular 
pustules, accompanied by high fever and leukocytosis. 
Mild oral mucous membrane involvement may occur in 
approximately 20 percent of AGEP. Pustules resolve spon-
taneously within a few (∼4 to 10) days and are followed 
by postpustular, pin-point desquamation. Undoubtedly, 
AGEP is improved by discontinuing the culprit medication 
and antibiotics are unnecessary unless there are signs of 
infection. Because AGEP is a self-limiting disease, sys-
temic steroid treatment is not always required
1.HT Shin, et al
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Fig. 3. Strong vesicular reaction to celecoxib diluted at 5% in 
normal saline after 48 hours.
Currently, several mechanisms of AGEP have been pro-
posed. Britschgi et al.
4 suggested the involvement of a 
drug-specific T cell, which produces interleukin (IL)-8 and 
IL-5. The other mechanisms are the formation of antigen- 
antibody complex by viral infection or medication that 
causes activating of the complement system
2.
Drug patch tests can be helpful in the defining the cause 
of AGEP
9. Based on the fact that the patch test shows 
positive results, AGEP is considered as a delayed type of 
hypersensitivity reaction. However, the usefulness of the 
drug patch test is dependent on the tested drug. Because 
of the possibility of false negative results, the drug patch 
test should be performed with high concentrations of the 
commercialized form of the medication. Thirty percent is 
the maximum concentration possible to get a uniform 
dilution in petrolatum or in water. In drug patch tests for 
celecoxib with concentration higher than 10 percent, 
irritant reactions were reported
9. To avoid false positive 
results by irritation, the patch test was performed with 
celecoxib diluted at 5 percent in normal saline and 
petrolatum and two healthy persons were also tested. The 
patient showed positive result and the two healthy persons 
showed negative results.
Celecoxib, a selective COX-2 inhibitor, is a non-steroidal 
anti-inflammatory drug for the reduction of pain. A num-
ber of skin adverse effects of celecoxib have been repor-
ted, including urticaria, anaphylasis, angioedema, ery-
thema multiforme, fixed drug eruption, vasculitis, Stevens- 
Johnson syndrome, sweet's syndrome, toxic epidermal 
necrolysis, and AGEP
5. Since celecoxib contains a sulfo-
namide substituent, it has the potential for cross-reacting 
with other sulfonamide antibiotics. However, some authors 
disagree as to the presence of structural differences 
between sulfonamide antibiotics with aromatic amines 
and other sulfonamide containing drugs with non-aromatic 
amines
5,6. In the case, the cross reaction had not been 
evaluated.
To the authors' knowledge, this is the first report of cele-
coxib-induced AGEP confirmed by patch test in Korean 
literature. Drug patch tests can be helpful in the defining 
the cause of AGEP, but there is no standardization for the 
test. Therefore, a sufficient literature review is essential for 
drug patch tests.
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